Literature DB >> 33099837

NTRK and other recently described kinase fusion positive uterine sarcomas: A review of a group of rare neoplasms.

Sabrina Croce1, Isabelle Hostein1, W Glenn McCluggage2.   

Abstract

The landscape of uterine sarcomas has greatly expanded in recent years to include neoplasms with recurrent gene fusions, such as BCOR and YWHAE translocated high-grade endometrial stromal sarcomas. Sophisticated molecular techniques have also resulted in the description of "new" entities associated with recurrent kinase fusions involving NTRK and RET as well as COL1A1-PDGFB rearranged uterine sarcomas. These rare neoplasms will be discussed in this review, highlighting that some of the underlying molecular events are clinically actionable and potentially susceptible to targeted therapy. While relatively few of these neoplasms have been described to date, likely being previously lumped under the spectrum of undifferentiated uterine sarcoma, the number of cases will expand in the future given their recognition and the increasing availability of molecular testing. These neoplasms have overlapping morphology (often with a "fibrosarcoma-like" appearance) and immunohistochemical features, and are characterized by variable clinical outcomes. Although immunohistochemistry may assist in some cases, a definitive subclassification requires confirmatory molecular studies. As these molecular assays may not be routinely available in most laboratories, referral to reference centers may be needed. In order to assist the pathologist, we suggest a diagnostic algorithm for routine practice when dealing with a malignant or potentially malignant uterine spindle cell neoplasm.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  COL1A1-PDGFB; NTRK; RET; molecular testing; sarcoma; uterus

Mesh:

Substances:

Year:  2020        PMID: 33099837     DOI: 10.1002/gcc.22910

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  7 in total

1.  Recurrent KAT6B/A::KANSL1 Fusions Characterize a Potentially Aggressive Uterine Sarcoma Morphologically Overlapping With Low-grade Endometrial Stromal Sarcoma.

Authors:  Abbas Agaimy; Blaise A Clarke; David L Kolin; Cheng-Han Lee; Jen-Chieh Lee; W Glenn McCluggage; Patrik Pöschke; Robert Stoehr; David Swanson; Gulisa Turashvili; Matthias W Beckmann; Arndt Hartmann; Cristina R Antonescu; Brendan C Dickson
Journal:  Am J Surg Pathol       Date:  2022-05-17       Impact factor: 6.298

2.  NTRK-Fusion Sarcoma of the Uterine Cervix: Report of 2 Cases With Comparative Clinicopathologic Features.

Authors:  Neshat Nilforoushan; Stephanie L Wethington; Hiro Nonogaki; John Gross; Russell Vang; Deyin Xing
Journal:  Int J Gynecol Pathol       Date:  2021-10-29       Impact factor: 3.326

Review 3.  Progress in the pathological arena of gynecological cancers.

Authors:  W Glenn McCluggage
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

4.  EML4-NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review.

Authors:  Xiaohe Dang; Tao Xiang; Can Zhao; Hao Tang; Pengfei Cui
Journal:  Front Med (Lausanne)       Date:  2022-04-28

5.  A rare case of recurrent ovarian cancer with TPM3-NTRK1 gene rearrangement: A case report.

Authors:  Yuta Endo; Takafumi Watanabe; Motonobu Saito; Katsuharu Saito; Rei Suzuki; Hideki Sano; Yutaka Natori; Eisaku Sasaki; Makiko Ueda; Norihito Kamo; Shigenori Furukawa; Shu Soeda; Koji Kono; Shigehira Saji; Keiya Fujimori
Journal:  Mol Clin Oncol       Date:  2022-02-23

Review 6.  NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies.

Authors:  Antonio Marchetti; Benedetta Ferro; Maria Paola Pasciuto; Claudia Zampacorta; Fiamma Buttitta; Emanuela D'Angelo
Journal:  Pathologica       Date:  2022-06

7.  The significance of the fusion partner gene genomic neighborhood analysis in translocation-defined tumors.

Authors:  Elaheh Mosaieby; Petr Martínek; Ondrej Ondič
Journal:  Mol Genet Genomic Med       Date:  2022-05-27       Impact factor: 2.473

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.